1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: Results from Cohort A of the MagnetisMM-3 study
    Meeting Abstract

    Bahlis, N. J.; Tomasson, M. H.; Mohty, M.; Niesvizky, R.; Nooka, A. K.; Manier, S.; Maisel, C.; Jethava, Y.; Martinez-Lopez, J.; Prince, H. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Raje, N.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Damore, M. A.; Jiang, S.; Basu, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Variability in pattern of mutational signatures in multiple myeloma as a function of racial origin
    Meeting Abstract

    Blaney, P.; Boyle, E. M.; Maclachlan, K. H.; Williams, L. S.; Gagler, D.; Sudha, P.; Poos, A. M.; Wang, Y.; Ghamlouch, H.; Tenenbaum, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • SARS-CoV-2 vaccinations do not lead to progression of monoclonal gammopathy of undetermined significance: Results from the population-based iStopMM screening study
    Meeting Abstract

    Palmason, R.; Eythorsson, E.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Ekberg, S.; Crowther, M.; Reed, E. R.; Oskarsson, J. Þ.; Sigurdardottir, G. A.; Aspelund, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prevalence of MGUS is high in the iStopMM study but the prevalence of IgA MGUS does not increase with age in the way other immunoglobulin subtypes do
    Meeting Abstract

    Love, T. J.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Aspelund, T.; Reed, E. R.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Predicting the need for upfront bone marrow sampling in individuals with MGUS: Derivation of a multivariable prediction model using the prospective population-based iStopMM cohort
    Meeting Abstract

    Eythorsson, E.; Rögnvaldsson, S.; Thorsteinsdóttir, S.; Reed, E. R.; Sigurdardóttir, G. Á.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardóttir, M.; Ólafsson, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save